Therefore, mutations and deletions of proteins related to this pathway on tumor cells, such as JAK1 and JAK2, STAT1, and IRF1, the IFNγ receptor chain, can lead to resistance to immune checkpoint inhibitors [18]. This evidence concerns the gene JAK2 and neoplasm.